|Bid||2.1600 x 1000|
|Ask||2.1800 x 1400|
|Day's Range||2.1300 - 2.2600|
|52 Week Range||1.7500 - 13.8000|
|Beta (5Y Monthly)||2.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 8.25% and -20.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs
Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer
Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) shareholders will doubtless be very grateful to see the share price up 33...
Lewis "Rusty" Williams founded Five Prime Therapeutics nearly 20 years ago. Now he, the co-inventor of the cancer drug Opdivo and two other Five Prime executives are deep into a new startup.
New York-born, Bay Area-raised Brian Wong is doing the hard work of broadening a drug pipeline with what he describes as a “Brooklyn toughness."
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -8.42% and -31.02%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...
This cancer-fighting biotech was one of the early companies to commit to The Cove at Oyster Point; now it may sublease some or all of its space.